Xilio Therapeutics Welcomes Caroline Hensley as Chief Legal Officer
Xilio Therapeutics, Inc. (NASDAQ: XLO), a dynamic company focused on innovating tumor-activated immuno-oncology therapies for cancer patients, is excited to announce the appointment of Caroline (Holda) Hensley as its new Chief Legal Officer. This key addition to the leadership team signifies a critical step in the company's journey towards advancing its strategic objectives.
Caroline Hensley's Extensive Experience in Biotechnology
Caroline Hensley comes to Xilio with a wealth of experience in the biotechnology sector. Before joining Xilio, she held the position of senior vice president, assistant general counsel, and chief compliance officer at Seres Therapeutics, Inc. In this role, she dealt with various corporate legal matters, compliance protocols, capital markets, as well as clinical and commercial operations.
Her tenure at Seres Therapeutics included steering crucial partnerships and ensuring full compliance with FDA and healthcare regulations. Hensley's insights will be invaluable as Xilio continues to navigate the complexities of the biotechnology landscape.
Academic Background and Legal Expertise
Hensley earned her B.A. in economics from the University of Texas at Austin and her J.D. from the Boston University School of Law. Her background equips her with a profound understanding of both business and legal frameworks, positioning her uniquely to guide Xilio’s legal strategies.
Leadership Quote on the Appointment
René Russo, Pharm.D., the president and CEO of Xilio Therapeutics, expressed enthusiasm about Hensley's appointment. He stated, "Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization. Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard."
Hensley’s Vision for Xilio Therapeutics
Caroline Hensley expressed her excitement for joining the Xilio team during what she describes as a pivotal moment in the company’s growth. "I am thrilled to join the Xilio team at this pivotal moment in the company's growth and look forward to helping to advance Xilio’s promising pipeline of novel, tumor-activated immuno-oncology therapies," stated Hensley.
About Xilio Therapeutics
Xilio Therapeutics is dedicated to revolutionizing cancer treatment by developing tumor-activated immuno-oncology (I-O) therapies. The company aims to improve cancer outcomes while minimizing the systemic side effects commonly associated with existing immunotherapies. Their proprietary platform focuses on creating and optimizing a range of novel clinical and preclinical I-O molecules.
Xilio’s approach includes the development of tumor-activated cytokines, antibodies, bispecifics, and immune cell engagers. By concentrating on localized anti-tumor activity within the tumor microenvironment, they aspire to significantly raise therapeutic indices, which is a critical measure of treatment efficacy.
Contact Information for Inquiries
For investor and media inquiries, please reach out to:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
Frequently Asked Questions
What role does Caroline Hensley have at Xilio Therapeutics?
Caroline Hensley has been appointed as the Chief Legal Officer, bringing significant experience in biotechnology law.
What experience does Hensley bring to Xilio?
She has extensive experience from her previous role at Seres Therapeutics, overseeing legal compliance and corporate matters.
What is Xilio Therapeutics' focus?
Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes.
How does Xilio plan to improve cancer therapies?
They aim to optimize therapeutic indices by localizing anti-tumor activity and minimizing systemic side effects.
How can I contact Xilio Therapeutics?
For inquiries, you can contact Scott Young, Vice President, Investor Relations and Corporate Communications via email at investors@xiliotx.com.
